| Not Yet Recruiting | Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model Influenza | Phase 2 | 2026-06-01 |
| Recruiting | Study of TRX-100 Tablets Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers Healthy Volunteer | Phase 1 | 2026-03-25 |
| Active Not Recruiting | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patient Influenza | Phase 2 | 2025-12-15 |
| Recruiting | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COV COVID - 19 | Phase 2 | 2025-09-16 |
| Completed | A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in He Healthy Volunteer Study | Phase 1 | 2024-08-13 |
| Completed | Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Hea Healthy Volunteers Only | Phase 1 | 2024-04-15 |
| Unknown | Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies Endometrioid Endometrial Cancer | Phase 1 / Phase 2 | 2023-03-29 |
| Unknown | Study of ON 123300 in Patients With Advanced Cancer Solid Tumors, Adult | Phase 1 | 2021-05-13 |
| Terminated | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts | Phase 3 | 2015-12-02 |
| Terminated | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors Neoplasms, Advanced Solid Tumor | Phase 1 | 2014-06-01 |
| Withdrawn | Three Dosing Schedules of Oral Rigosertib in MDS Patients Myelodysplastic Syndrome | Phase 1 | 2014-05-01 |
| Completed | Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers Healthy | Phase 1 | 2014-01-01 |
| Completed | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 1 | 2014-01-01 |
| Completed | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | 2013-08-01 |
| Completed | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decit Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia | Phase 3 | 2013-08-01 |
| Completed | Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs Myelodysplastic Syndromes | Phase 2 | 2013-07-01 |
| Completed | Oral Rigosertib for Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma | Phase 2 | 2013-03-01 |
| Completed | Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplast Myelodysplastic Syndrome, MDS, Trisomy 8 | Phase 2 | 2012-05-01 |
| Completed | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma | Phase 3 | 2011-05-01 |
| Completed | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Myelodysplastic Syndromes, MDS, RAEB | Phase 3 | 2010-11-01 |
| Completed | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute L Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Disease | Phase 1 / Phase 2 | 2010-07-01 |
| Completed | Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors Solid Tumor | Phase 1 | 2010-07-01 |
| Completed | Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors Solid Tumor | Phase 1 | 2010-01-01 |
| Completed | Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome Myelodysplastic Syndrome | Phase 1 | 2009-12-01 |
| Terminated | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia Lymphoma, Acute Lymphocytic Leukemia | Phase 1 | 2009-11-01 |
| Completed | Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Myelodysplastic Syndrome | Phase 2 | 2009-05-01 |
| Withdrawn | Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome Myelodysplastic Syndrome | Phase 1 / Phase 2 | 2009-03-01 |
| Completed | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients Ovarian Cancer | Phase 2 | 2009-03-01 |
| Completed | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2009-01-01 |
| Completed | Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors Malignant Neoplasmas, Solid Tumors | Phase 1 | 2009-01-01 |
| Completed | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia | Phase 1 | 2008-10-01 |
| Completed | Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma Hepatoma, Advanced Solid Tumor | Phase 1 | 2008-06-01 |
| Completed | Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin Advanced Solid Tumors | Phase 1 | 2008-02-01 |
| Completed | Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer Advanced Cancer, Solid Tumors, Cancer | Phase 1 | 2006-08-01 |
| Completed | Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer Solid Tumors, Advanced Cancer, Cancer | Phase 1 | 2006-06-01 |